<DOC>
	<DOC>NCT00809705</DOC>
	<brief_summary>This 3 arm, placebo-controlled study will investigate the effect of Taspoglutide on gastric emptying in patients with type 2 diabetes. Patients will be randomized into one of 3 groups to receive a)10mg Taspoglutide sc weekly for 12 weeks b)10mg Taspoglutide sc weekly for 4 weeks followed by 20mg Taspoglutide sc weekly for 8 weeks or c) placebo sc weekly for 12 weeks, with all injections administered in the abdomen.Gastric emptying will be assessed by a paracetamol test at intervals during the study. The anticipated time on study treatment is 3 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patients, 1875 years of age; type 2 diabetes mellitus, treated with stable oral antidiabetic drug therapy for &gt;=3 months prior to screening; stable weight +/10% for &gt;=3 months before screening. type 1 diabetes mellitus; acute gastrointestinal symptoms at screening and/or day 1; clinically relevant cardiovascular, bronchopulmonary, gastrointestinal or neurological disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>